Claris Lifesciences IPO
Claris Lifesciences IPO — date, price band, lot size & details 2010
Claris Lifesciences listed on 20 Dec 2010 at ₹224.4, 1.6% below the ₹228 issue price.
Claris Lifesciences is an Ahmedabad based maker of sterile injectables, one of the largest in India, with a presence in 76 countries. Its total income was Rs 645.80 crore in the year to December 2009.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 15 November.
- Open 24 Nov 2010
- Close 02 Dec 2010
- Allotment 15 Dec 2010
- Refund/credit TBA
- Listing 20 Dec 2010
Issue summary
The terms of the offer, as filed.
| IPO Dates | 24 Nov to 2 Dec, 2010 |
|---|---|
| Price Band | ₹228 – ₹235 |
| Face Value | ₹10 |
| Lot Size | 22 Shares |
| Issue Size | ₹300 Cr |
| Sale Type | Fresh capital only |
| Listing On | BSE |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 5,016 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 22 shares at the ₹228 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 22 | ₹5,016 |
| Retail (max) | 39 | 858 | ₹1,95,624 |
| S-HNI (min) | 40 | 880 | ₹2,00,640 |
| S-HNI (max) | 199 | 4,378 | ₹9,98,184 |
| B-HNI (min) | 200 | 4,400 | ₹10,03,200 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 4
- 01It had a presence in 76 countries and 128 products.
- 02Total income rose from Rs 572.20 crore in 2007 to Rs 645.80 crore in 2009.
- 03Net worth rose from Rs 315.19 crore at the end of 2007 to Rs 512.38 crore on 31 May 2010.
- 04Rs 131.59 crore of the issue was for a new plant making parenterals, bags and fat emulsions.
Risks · 5
- 01Profit after tax fell from Rs 114.56 crore in 2008 to Rs 70.86 crore in 2009.
- 02Total income fell from Rs 695.77 crore in 2008 to Rs 645.80 crore in 2009.
- 03Total borrowing was Rs 370.52 crore on 31 May 2010.
- 04Exports to 76 countries bring currency and regulatory risk, and the issue was priced at Rs 228, the bottom of its band.
- 05Its off patent products face price competition; promoters held 86.03% before the issue.
Three years of numbers
All figures in ₹ crore, as reported in the Claris Lifesciences offer document.
| Metric | 31 May 2010 | 31 Dec 2009 | 31 Dec 2008 | 31 Dec 2007 |
|---|---|---|---|---|
| Assets | 1,181.53 | 1,159.03 | 1,044.88 | 798.90 |
| Total Income | 268.56 | 645.80 | 695.77 | 572.20 |
| Profit After Tax | 29.69 | 70.86 | 114.56 | 82.29 |
| NET Worth | 512.38 | 485.43 | 426.54 | 315.19 |
| Reserves and Surplus | 463.93 | 451.30 | 336.85 | 225.50 |
| Total Borrowing | 370.52 | 314.01 | 330.71 | 225.55 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Claris Lifesciences RHP.
Where the money goes
₹274.27 Cr of the issue is earmarked to named objects.
Claris Lifesciences IPO Anchor Investors
4 anchor investors across 1 fund house committed ₹54.00 Cr a day before the issue opened.
| Anchor Investor | Fund House | Shares | Amount (₹ Cr) | % of Anchor Book |
|---|---|---|---|---|
| Tree Line Asia Master Fund (Singapore) Pte Ltd | - | 927,441 | 27.17 | 50.32% |
| Ashoka Flowering Tree Mauritius | - | 463,721 | 13.59 | 25.16% |
| Indea Capital Pte Ltd A/C Indea Absolute Return Fund | - | 297,268 | 8.71 | 16.13% |
| Indea Capital Pte Ltd A/C Indea Long Term Opportunities Master Fund | - | 154,573 | 4.53 | 8.39% |
| Total anchor allocation | 54.00 | |||
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
It is one of the largest Indian sterile injectables companies, with a presence in 76 countries. Its offering of 128 products is entirely off patent, and most can be injected directly and are used to treat critical illnesses.
Its products cover anaesthesia, critical care, anti infectives, renal care, infusion therapy, enteral and parenteral nutrition and oncology.
The IPO was Rs 300 crore and was entirely fresh issue at Rs 228, the bottom of the Rs 228 to Rs 235 band. The money was for a new injectables plant, a propofol line, an R&D facility and prepaying a term loan.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Claris Lifesciences IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
JM Financial Ltd.
172 issues handledBest listing: Tata Technologies (+140.0%). Weakest: ACME Solar Holdings (-13.1%).
Axis Capital
256 issues handledBest listing: Latent View Analytics (+160.0%). Weakest: Shriram Properties (-23.7%).
ICICI Securities
221 issues handledBest listing: Latent View Analytics (+160.0%). Weakest: Bannari Amman Spinning Mills (-25.2%).
Edelweiss Financial Services Ltd
73 issues handledBest listing: Route Mobile (+104.9%). Weakest: ICICI Securities (-16.3%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Claris Lifesciences?
The current Grey Market Premium is ₹0.
What is the Claris Lifesciences IPO price band?
₹228 to ₹235, on a face value of ₹10.
When is the allotment?
The basis of allotment is 15 December 2010, with listing on 20 December 2010.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
